CollPlant Biotechnologies (CLGN) EBT Growth (3y) (2020 - 2026)
Powered by 
Analysis
CollPlant Biotechnologies (CLGN) EBT Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 19.70% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -103.74% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 6.22% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 12.16% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 103.79% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 24.03% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 38.36% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -42.82% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | CollPlant Biotechnologies | 4.17 Mn | 4.17 Mn | -243,000.00 | -42.36% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 30, 2026 | -42.36% |
| Dec 31, 2025 | 12.34% |
| Sep 30, 2025 | 7.76% |
| Jun 30, 2025 | 40.26% |
| Mar 30, 2025 | -34.58% |
| Dec 31, 2024 | -1.74% |
| Sep 30, 2024 | -14.59% |
| Jun 30, 2024 | 51.50% |
| Mar 31, 2024 | -24.59% |
| Dec 31, 2023 | -22.87% |
| Sep 30, 2023 | -102.08% |
| Jun 30, 2023 | 70.82% |
| Mar 31, 2023 | 59.89% |
| Dec 31, 2022 | 13.59% |
| Sep 30, 2022 | -132.39% |
| Jun 30, 2022 | -55.31% |
| Mar 31, 2022 | 21.65% |
| Dec 31, 2021 | -50.46% |
| Sep 30, 2021 | -60.43% |
| Jun 30, 2021 | -67.79% |